Catalyst Event
Regeneron Pharmaceuticals Inc (REGN) · Other
From KEDI Tesla Fixed Tech100 Index (KTSLT100)
4/22/2026, 12:00:00 AM
On April 22, 2026, the FDA approved Dupixent for use in young children with uncontrolled chronic spontaneous urticaria (CSU), expanding the market for the key drug. Medium importance is estimated due to the expansion of a major revenue driver.
Korean Translation
2026년 4월 22일, FDA는 통제되지 않는 만성 특발성 두드러기(CSU)를 앓는 어린이를 대상으로 듀픽센트 사용을 승인하여 이 주요 약물의 시장을 확대함. 주요 수익원의 시장 확대로 인해 중요도를 'Medium'으로 예상함.
Related Recent Events
Cadence Design Systems Inc (CDNS) · Earnings Release
Q2 2026 earnings release scheduled for July 27, 2026. Medium importance is estimated as investors will monitor the impact of recent acquisitions on the updated guidance, scheduled.
7/27/2026, 12:00:00 AM
Netflix Inc (NFLX) · Earnings Release
Netflix is expected to announce its Q2 2026 financial results on 2026-07-16 based on past reporting schedules; low impact is estimated as this is a routine announcement expected.
7/16/2026, 12:00:00 AM
Telefonaktiebolaget LM Ericsson (publ) (ERIC) · Earnings Release
Second quarter 2026 earnings report scheduled for July 14, 2026. A price impact of at least 5% is estimated based on historical volatility; scheduled.
7/14/2026, 12:00:00 AM
Honeywell International Inc (HON) · Trading Issue
The spin-off of the Honeywell Aerospace business is scheduled to be completed on June 29, 2026. This major corporate action will change share counts and is expected to have a high price impact, scheduled.
6/29/2026, 12:00:00 AM
QUALCOMM Inc. (QCOM) · Other
Qualcomm has scheduled an Investor Day for June 24, 2026, where it is expected to provide updates on its strategy and long-term outlook, scheduled. Low importance is estimated as such events typically result in price impacts of at least 1%.
6/24/2026, 12:00:00 AM
Automatic Data Processing Inc (ADP) · Other
Quarterly dividend of $1.70 per share, ex-dividend date scheduled for 2026-06-12; price impact of at least 1% expected.
6/12/2026, 12:00:00 AM